Zoledronic acid: Hypocalcaemia.

A 69-year-old woman experienced hypocalcemia after being given an incorrect dose of zoledronic acid for bone pain. She was also found to have lack of efficacy during treatment with gemcitabine for papillary urothelial carcinoma of the bladder. The woman initially presented with hematuria and severe bone pain, and was diagnosed with high-grade papillary urothelial carcinoma with multiple lytic lesions. Despite the medication error, her condition appeared to improve initially, but her bone pain worsened again and she ultimately passed away 13 months after diagnosis. [Extracted from the article]

Copyright of Reactions Weekly is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)